- Home
- OBIO vs FLC Comparison
OBIO vs FLC Comparison
Compare OBIO & FLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OBIO
- FLC
- Stock Information
- Founded
- OBIO 2017
- FLC 2003
- Country
- OBIO United States
- FLC United States
- Employees
- OBIO N/A
- FLC N/A
- Industry
- OBIO Medicinal Chemicals and Botanical Products
- FLC Trusts Except Educational Religious and Charitable
- Sector
- OBIO Health Care
- FLC Finance
- Exchange
- OBIO Nasdaq
- FLC Nasdaq
- Market Cap
- OBIO 151.3M
- FLC 171.6M
- IPO Year
- OBIO N/A
- FLC N/A
- Fundamental
- Price
- OBIO $2.89
- FLC $16.59
- Analyst Decision
- OBIO Strong Buy
- FLC
- Analyst Count
- OBIO 5
- FLC 0
- Target Price
- OBIO $14.20
- FLC N/A
- AVG Volume (30 Days)
- OBIO 193.1K
- FLC 37.8K
- Earning Date
- OBIO 05-12-2025
- FLC 01-01-0001
- Dividend Yield
- OBIO N/A
- FLC 6.64%
- EPS Growth
- OBIO N/A
- FLC N/A
- EPS
- OBIO N/A
- FLC N/A
- Revenue
- OBIO $2,886,000.00
- FLC N/A
- Revenue This Year
- OBIO $21.38
- FLC N/A
- Revenue Next Year
- OBIO $31.89
- FLC N/A
- P/E Ratio
- OBIO N/A
- FLC N/A
- Revenue Growth
- OBIO 30.23
- FLC N/A
- 52 Week Low
- OBIO $2.37
- FLC $12.62
- 52 Week High
- OBIO $8.87
- FLC $15.45
- Technical
- Relative Strength Index (RSI)
- OBIO 48.11
- FLC 63.90
- Support Level
- OBIO $2.76
- FLC $16.35
- Resistance Level
- OBIO $3.02
- FLC $16.88
- Average True Range (ATR)
- OBIO 0.18
- FLC 0.17
- MACD
- OBIO 0.03
- FLC 0.01
- Stochastic Oscillator
- OBIO 52.06
- FLC 100.00
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the global commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.
About FLC Flaherty & Crumrine Total Return Fund Inc
Flaherty & Crumrine Total Return Fund Inc is a diversified, closed-end investment management company. Its investment objective is to provide its common shareholders with a high current income. The fund's secondary investment objective is capital appreciation.